Therapeutic use of antibodies to hgf
AssigneeAlderbio Holdings LLC
InventorsLeon F. Garcia-Martinez, Andrew Lawrence Feldhaus, Katherine Olson, Benjamin H. Dutzar, John A. Latham
Life of this patent
Estimating the term…
Abstract
The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.
Claims71
-160. (canceled)
An anti-human hepatocyte growth factor (HGF) antibody or antibody fragment which specifically binds to the same or overlapping epitope(s) and/or competes for binding to the same or overlapping epitope(s) on an intact human HGF polypeptide or fragment thereof as an anti-human HGF antibody selected from Ab1, Ab2, Ab7, Ab8, Ab9, Ab10, Ab12, Ab14, Ab19, Ab21, Ab23, Ab24, Ab25, and Ab28.
(canceled)
(canceled)
(canceled)
-167. (canceled)
-182. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-237. (canceled)
-248. (canceled)
-259. (canceled)
-278. (canceled)
-348. (canceled)
-360. (canceled)
-370. (canceled)
Dependencies are inferred from the claim text.